Developing Multi-Targeted T-Cell Engagers With Deck Bio’s Johanna Kaufmann
In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Deck Bio’s chief scientific officer, Johanna Kaufmann, to discuss the company’s multi-peptide-MHC-targeted T-cell engager platform for solid tumors. Kaufmann explains the platform and reflects on the company’s journey through preclinical development. Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichi...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Better Biopharma
2026 Regulatory Updates And Operation TrialBlazer
Focusing On Quality Unit Independence With Tatyana Matveeva, Ph.D.
Fixing AAV Recovery With Siren Biotechnology’s Nathalie Clément, Ph.D.
Digitalizing The Biopharma Ecosystem With Kat Kozyrytska
Get summaries like this every morning.
Free AI-powered recaps of Better Biopharma and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.